专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004046345A3 USE OF HMGB FRAGMENTS AS ANTI-INFLAMMATORY AGENTS 审中-公开
标题翻译： HMGB碎片作为抗炎剂使用
公开(公告)号：WO2004046345A3
公开(公告)日：2004-12-02
申请号：PCT/US0337507
申请日：2003-11-20
申请人： CRITICAL THERAPEUTICS INC , NEWMAN WALTER , O'KEEFE THERESA L
发明人： NEWMAN WALTER , O'KEEFE THERESA L
IPC分类号： A61K38/00 , A61K38/17 , C07K14/47 , A61K39/00 , C07K7/00
CPC分类号： C07K14/47 , A61K38/1709
摘要： Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise an HMGB A box, and/or an antibody preparation that specifically binds to an HMGB B box, and/or an inhibitor of TNF biological activity. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.
摘要翻译：公开了用于抑制细胞中促炎细胞因子的释放和抑制患者中炎性细胞因子级联的组合物和方法。该组合物包含HMGB A盒和/或与HMGB B盒特异性结合的抗体制剂，和/或TNF生物学活性的抑制剂。该方法包括用足够量的组合物处理细胞或患者以抑制促炎细胞因子的释放或抑制炎性细胞因子级联。

2. 发明申请

WO2005026209A3 MONOCLONAL ANTIBODIES AGAINST HMGB1 审中-公开
标题翻译：单克隆抗体对HMGB1
公开(公告)号：WO2005026209A3
公开(公告)日：2005-09-15
申请号：PCT/US2004029527
申请日：2004-09-10
申请人： CRITICAL THERAPEUTICS INC , NEWMAN WALTER , QIN SHIXIN , O'KEEFE THERESA , OBAR ROBERT
发明人： NEWMAN WALTER , QIN SHIXIN , O'KEEFE THERESA , OBAR ROBERT
IPC分类号： C07K14/47 , C07K16/18 , C12N5/20 , A61K39/395
CPC分类号： C07K14/4718 , A61K2039/505 , C07K16/24 , C07K2317/34 , C07K2317/565 , C07K2317/76 , Y10S435/81
摘要： In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade and methods of detecting an HMGB polypeptide in a sample.
摘要翻译：在各种实施方案中，本发明涉及结合脊椎动物高迁移率组盒（HMGB）多肽的抗体或其抗原结合片段，检测和/或鉴定与HMGB多肽结合的试剂的方法，治疗方法特征在于激活炎性细胞因子级联的受试者的病症以及检测样品中的HMGB多肽的方法。

3. 发明申请

WO2006012373A2 HMGB COMBINATION THERAPIES 审中-公开
标题翻译： HMGB组合治疗
公开(公告)号：WO2006012373A2
公开(公告)日：2006-02-02
申请号：PCT/US2005025799
申请日：2005-07-20
申请人： CRITICAL THERAPEUTICS INC , NEWMAN WALTER
发明人： NEWMAN WALTER
CPC分类号： C07K16/24 , A61K38/1703 , A61K45/06 , A61K2300/00
摘要： Compositions and methods are disclosed for treating a condition characterized by activation of an inflammatory cytokine cascade in a patient. The compositions comprise an HMGB A box and an inhibitor of complement biological activity, and/or an antibody that binds an HMGB polypeptide or biologically active fragment thereof and an inhibitor of complement biological activity, and/or an inhibitor of HMGB receptor binding and an inhibitor of complement biological activity. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of proinflammatory cytokine(s) and/or inhibit the inflammatory cytokine cascade.
摘要翻译：公开了用于治疗特征在于患者中炎性细胞因子级联活化的病症的组合物和方法。组合物包含HMGB A盒和补体生物活性抑制剂，和/或结合HMGB多肽或其生物活性片段和补体生物活性抑制剂的抗体，和/或HMGB受体结合抑制剂和抑制剂的补体生物活性。所述方法包括用足够量的组合物治疗细胞或患者以抑制促炎细胞因子的释放和/或抑制炎性细胞因子级联。

4. 发明申请

WO2008085875A2 METHOD FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH INCREASED 5-LIPOXYGENASE AND/OR LEUKOTRIENE ACTIVITY 审中-公开
标题翻译：用于治疗与增加的5-LIPOXYGENASE和/或LEUKOTRIENE活性相关的条件的方法
公开(公告)号：WO2008085875A2
公开(公告)日：2008-07-17
申请号：PCT/US2008000101
申请日：2008-01-04
申请人： CRITICAL THERAPEUTICS INC , NEWMAN WALTER , KUMAR ANJALI , LIBERTINE LYNNE
发明人： NEWMAN WALTER , KUMAR ANJALI , LIBERTINE LYNNE
IPC分类号： A61K31/381 , A61P11/00 , A61P11/06
CPC分类号： A61K31/381
摘要： The invention pertains to a method of treating a condition mediated by or characterized by increased 5-lipoxygenase activity in a patient suffering therefrom comprising administering to said patient a composition comprising (R)-zileuton and a pharmaceutically acceptable excipient, wherein said composition is substantially free of (S)-zileuton.
摘要翻译：本发明涉及一种治疗患有此患者的5-脂氧合酶活性增加或由其特征增加的病症的方法，其包括向所述患者施用包含（R） - 齐尼妥和药学上可接受的赋形剂的组合物，其中所述组合物基本上是游离的（S）-zileuton。

5. 发明申请

WO2005030793A3 ANTIBODIES WHICH BIND HUMAN CXCR3 审中-公开
标题翻译：抗体人类CXCR3
公开(公告)号：WO2005030793A3
公开(公告)日：2006-01-05
申请号：PCT/US2004031445
申请日：2004-09-24
申请人： MILLENNIUM PHARM INC , QIN SHIXIN , KASSAM NASIM , NEWMAN WALTER
发明人： QIN SHIXIN , KASSAM NASIM , NEWMAN WALTER
IPC分类号： A61K39/395 , C07H21/04 , C07K20060101 , C07K16/28 , C12N5/06
CPC分类号： C07K16/2866 , A61K47/6849 , A61K2039/505 , C07K2317/21 , C07K2317/565 , C07K2317/76
摘要： Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods which employ the antibodies and antigen-binding fragments.
摘要翻译：公开了结合人CXCR3的抗体的抗体和抗原结合片段。在优选的实施方案中，抗体是人。还公开了编码抗体或其部分的核酸和载体，含有核酸的重组细胞，以及包含抗体或抗原结合片段的组合物。本发明还提供了使用抗体和抗原结合片段的治疗和诊断方法。

6. 发明申请

WO0005265A3 ANTI-CRR2 ANTIBODIES AND METHODS OF USE THEREFOR 审中-公开
标题翻译：抗CRR2抗体及其使用方法
公开(公告)号：WO0005265A3
公开(公告)日：2000-04-27
申请号：PCT/US9916452
申请日：1999-07-22
申请人： LEUKOSITE INC , LAROSA GREGORY J , HORVATH CHRISTOPHER , NEWMAN WALTER
发明人： LAROSA GREGORY J , HORVATH CHRISTOPHER , NEWMAN WALTER
IPC分类号： G01N33/53 , A61K39/395 , A61P9/10 , A61P29/00 , A61P31/18 , A61P37/02 , A61P43/00 , C07K16/00 , C07K16/28 , C12N5/10 , C12N15/02 , C12N15/09 , C12P21/08 , C12Q1/02 , C12R1/91 , G01N33/566 , G01N33/577
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/76
摘要： The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor (2) (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
摘要翻译：本发明涉及与哺乳动物（例如人）CC-趋化因子受体（2）（CCR2）或部分受体结合并阻断配体与受体结合的抗体或其功能片段。本发明进一步涉及抑制携带哺乳动物CCR2的细胞与其配体的相互作用的方法，以及该抗体和片段在治疗，预防和诊断方法中的用途。

7. 发明申请

WO9800535A3 Method for inhibiting HIV-1 infection, drug screens, and method of diagnosis and prognosis of sysceptibility to HIV infection 审中-公开
标题翻译：抑制HIV-1感染的方法，药物筛选，以及HIV感染系统的诊断和预后的方法
公开(公告)号：WO9800535A3
公开(公告)日：1998-06-18
申请号：PCT/US9712701
申请日：1997-06-27
申请人： DANAFARBER CANCER INST , SODROSKI JOSEPH G , NEWMAN WALTER , CHOE HYE-RYUN , WU LIJUN , GERARD NORMA , GERARD CRAIG
发明人： SODROSKI JOSEPH G , NEWMAN WALTER , CHOE HYE-RYUN , WU LIJUN , GERARD NORMA , GERARD CRAIG
IPC分类号： A61K38/00 , A61K38/19 , A61K49/00 , C07K14/16 , C07K14/715 , C07K16/28 , C12N15/85 , G01N33/50 , G01N33/569 , C12N15/09 , A01K67/027 , A61K39/395 , A61K47/48 , G01N33/68
CPC分类号： G01N33/5091 , A01K2217/05 , A01K2227/10 , A01K2267/0337 , A61K38/00 , C07K14/005 , C07K14/7158 , C07K16/2866 , C12N15/8509 , C12N2740/16122 , G01N33/5008 , G01N33/5088 , G01N33/56988 , G01N2333/162 , G01N2333/715
摘要： Novel β chemokine receptors that facilitate cellular entry of primary macrophage-tropic HIV-1 strains are described. CCR5 and CCR3 broadly facilitate entry of macrophage-tropic HIV-1 strains. A gp120 conformational binding site that is formed by the binding of gp120 and CD4 which permits binding of the complex to the chemokine receptors is also disclosed. Binding assays which permit the ready screening for molecules which affect the binding of gp120 and the chemokine are taught as well as specific targets for affecting the binding.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式